Pretax profit at the main Irish unit of pharma giant Johnson & Johnson surged 58 per cent to €3.6 billion last year.
New accounts filed by the Cork-based Janssen Sciences UC show the business recorded the sharp increase in profit as revenue rose 9 per cent to €8.79 billion in the 12 months to January 2nd.
A breakdown of the firm’s revenue shows €153 million in sales were recorded in the Republic, €4.45 billion in North America, €4.09 billion in EMEA; €52.46 million in Latin America; and €33.4 million in Asia Pacific.
A subsidiary of US-headquartered Johnson & Johnson, the Ringaskiddy-registered firm recorded a post-tax profit of €3.2 billion after paying corporation tax of €396 million.
‘I have invested in shares and I have done well, but also not so well’
Is Fair Deal really ‘fair’ if it is effectively taxing savings from already taxed income?
Warren Buffett’s approach to errors offers important lesson for other business leaders
UK needs new EU trade deal, not scraps from the White House
The firm enjoyed the rise in earnings after the company reversed a 2020 non-cash impairment of €635.8 million relating to its investment in subsidiary Janssen Irish Finance Unlimited Company.
The increased profit last year also takes account of a €137 million gain on the sale of intellectual property offset by finance expenses of €294.84 million.
The directors disclose that the firm proposed a dividend payout of €5 billion earlier this month on November 15th last to Janssen R&D Ireland UC.
Numbers employed by the business last year increased from 725 to 835 and staff costs totalled €98.27 million.
Twelve directors – 10 of whom are Irish – served on the firm’s board last year and shared pay of €3.05 million included pension contributions of €259,000.
The profit last year takes account of €902.07 million in non-cash amortisation costs and €1.18 billion in research and development costs.
The company had shareholder funds of €36.1 billion on January 2nd, which was an increase of €6.5 billion on the financial position one year earlier.
The directors state that this is primarily due to the profit for the financial year of €3.2 billion and a capital contribution of €3.31 billion from Janssen R&D Ireland Unlimited Company.
They state that in a post-balance-sheet event on January 20th they approved a proposal for a further capital injection of €2.8 billion into subsidiary Janssen Irish Finance Unlimited Company.
